Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer
NCT07305246Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by First Hospital of China Medical University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07305246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07305246.